Ionis Pharmaceuticals IONS Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's proceeds from exercises of stock options and other stock issuances?
- Ionis Pharmaceuticals (IONS) reported proceeds from exercises of stock options and other stock issuances of $57.3M in Q1 2026.
- How has Ionis Pharmaceuticals's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Ionis Pharmaceuticals's proceeds from exercises of stock options and other stock issuances increased by 2457.0% year-over-year, from $2.24M to $57.3M.
- What is the long-term trend for Ionis Pharmaceuticals's proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's proceeds from exercises of stock options and other stock issuances has grown at a 102.0% compound annual growth rate (CAGR), from $11.57M to $192.6M.